Topic: physician speakers
A new study suggests that the consistency of payments from drugmakers to doctors matters the most when it comes to swaying prescribing habits.
The U.S. Senate has released a report on Insys that provides an insider’s view of a company leaning on physicians to help drive sales.
GlaxoSmithKline is rolling back its strict no-payments-to-doctors policy to allow some exceptions for select products and countries.
Kickbacks whistleblowers reached their "put up or shut up" moment for producing solid evidence—and didn't, Teva says.
The feds charged five doctors over accepting Insys' bribes and said they've secured cooperation from two former employees.
California lawmakers are weighing a bill that would cut off most drugmaker payments to physicians, including speaking fees for that staple of pharma marketing, the slideshow over dinner.
A new JAMA study offers more evidence that doctors who collect more pharma payments prescribe more branded meds. Now, it's statin scripts at center: The higher the dollar amount, the higher the rate of brand scripts, rather than cheap generics.